Colorectal disorders:
Indications for: UCERIS
Induction of remission in patients with active, mild to moderate ulcerative colitis.
Adult Dosage:
Swallow whole. 9mg once daily in the AM for up to 8 weeks.
Children Dosage:
Not established.
UCERIS Warnings/Precautions:
Active or quiescent tuberculosis, untreated fungal, bacterial, systemic viral or parasitic infections. Supplement with systemic glucocorticosteroid in surgery or other stress situations. Caution when transferring from steroids with high systemic availability (monitor). May unmask allergies previously controlled by systemic corticosteroids. If exposed to chickenpox or measles, consider immune globulin or antiviral prophylactic therapies. Hypertension. Diabetes. Osteoporosis. Peptic ulcer. Glaucoma. Cataracts. Moderate to severe liver disease: monitor for hypercorticism; consider discontinuing if occurs. Elderly. Pregnancy. Nursing mothers.
UCERIS Classification:
Glucocorticoid.
UCERIS Interactions:
May be potentiated by CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin); consider discontinuing. Avoid grapefruit or grapefruit juice. May be affected by gastric acid reducing agents (eg, PPIs, H2-blockers, antacids).
Adverse Reactions:
Headache, nausea, decreased blood cortisol, upper abdominal pain, fatigue, flatulence, abdominal distension, acne, urinary tract infection, arthralgia, constipation; hypercorticism, adrenal suppression, immunosuppression.
Generic Drug Availability:
NO
How Supplied:
Ext-rel tabs—30
